Recombinant Human CCR9 Protein(HEK293)

CCR9 (C-C chemokine receptor type 9) is a chemokine receptor predominantly expressed in the immune system, particularly in T cells. It plays a crucial role in immune responses by mediating the migration of leukocytes to sites of inflammation and is involved in various pathological conditions, including inflammatory bowel disease (IBD) and certain types of cancer. The receptor's specific ligand, CCL25 (also known as TECK), is primarily produced in the intestines, highlighting the importance of CCR9 in gut immunity. Given its significant role in these diseases, CCR9 has emerged as a potential therapeutic target. Research efforts have increasingly focused on the development of CCR9-targeted therapies, including monoclonal antibodies and small molecules aimed at inhibiting its function. By producing and studying CCR9 recombinant proteins, researchers can gain valuable insights into its structure, signaling mechanisms, and interactions with ligands, paving the way for the development of innovative treatments. Understanding CCR9's role in immune cell trafficking and its involvement in disease pathology could lead to novel strategies for managing IBD and other conditions characterized by dysregulated immune responses. Overall, the exploration of CCR9 through recombinant protein studies holds promise for advancing our understanding of immune regulation and developing targeted therapies to improve patient outcomes.